睿知中国疾病研究地图
候选清单0

正在招募胃癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

ClinicalTrials.gov 上登记的一项胃癌开放试验。牵头方不是本站收录的医院;本站收录的 2 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 2

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心北京协和医院Peking Union Medical College Hospital北京医院页面
  2. 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07114601,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Must have histologically or cytologically proven diagnosis of locally advanced, unresectable, or metastatic cancer.

    入选标准第 1 条

    Must have the following histologically or cytologically confirmed diagnosis:

    入选标准第 6 条

    For participants with breast cancer diagnosis, where possible, ER and HER2 status should be assessed from the most recent tissue biopsy taken at the time of presentation with recurrent or metastatic disease.

    入选标准第 16 条

    To fulfill the requirement for ER+ disease by local testing, a tumor must express the ER immunohistochemistry, as defined in the relevant American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.

    入选标准第 17 条

  3. Phase 1a (Cohort A1 and A2) only: Previously received radiopharmaceutical or radioligand therapy. For participants with prostate cancer, prior ¹⁷⁷Lu-prostate-specific membrane antigen (PSMA) is permitted.

    排除标准第 1 条

    Previously received any prior hemi-body or whole-body radiotherapy, or prior external beam radiation therapy (EBRT) to greater than 25% of the bone marrow.

    排除标准第 3 条

  4. Must have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 1.

    入选标准第 19 条

  5. Must be assessed by computed tomography (CT)/magnetic resonance imaging (MRI) to confirm at least 1 of the following:

    入选标准第 2 条

    At least 1 measurable target lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    入选标准第 3 条

    If only bone lesions are present without a soft-tissue component, a bone scan or MRI must confirm at least 2 detectable lesions considered to represent active metastases

    入选标准第 4 条

  6. Have known active hepatitis B virus (HBV). Exception: Individuals with chronic HBV if they:

    排除标准第 6 条

    Have undetectable HBV DNA ≤14 days of C1D1.

    排除标准第 10 条

    Have known active hepatitis C virus (HCV). Exception: Individuals previously treated for HCV if they:

    排除标准第 11 条

    Have an HCV viral load below the limit of quantification ≤14 days of C1D1 and.

    排除标准第 13 条

    Are positive for anti-HCV antibodies and negative for HCV ribonucleic acid (RNA) before randomization.

    排除标准第 14 条

    Have untreated human immunodeficiency virus (HIV) infection. Exception: Individuals who have well-controlled HIV infection/disease and they:

    排除标准第 15 条

    Has an active second malignancy unless in remission with life expectancy greater than 2 years.

    排除标准第 20 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07114601,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Must have histologically or cytologically proven diagnosis of locally advanced, unresectable, or metastatic cancer.
  2. Must be assessed by computed tomography (CT)/magnetic resonance imaging (MRI) to confirm at least 1 of the following:
  3. At least 1 measurable target lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  4. If only bone lesions are present without a soft-tissue component, a bone scan or MRI must confirm at least 2 detectable lesions considered to represent active metastases
  5. Must have GRPR-positive disease, defined by investigator assessment of GRPR imaging.
  6. Must have the following histologically or cytologically confirmed diagnosis:
  7. Estrogen receptor (ER+)/human epidermal growth factor receptor 2 (HER2-) breast cancer
  8. ER+/HER2+ breast cancer
  9. Esophageal squamous cell carcinoma
  10. Adenocarcinoma of the stomach, gastroesophageal junction, or esophagus
  11. Colorectal carcinoma
  12. Metastatic castration-resistant prostate cancer
  13. Endometrial carcinoma. Carcinosarcoma is eligible. Uterine leiomyosarcoma, adenosarcoma, or endometrial stromal sarcoma is not eligible.
  14. Low-grade papillary serous ovarian cancer
  15. Other non-Central Nervous System (CNS) primary GRPR-positive solid tumors (Cohorts A1 dose escalation and D1 dose expansion only)
  16. For participants with breast cancer diagnosis, where possible, ER and HER2 status should be assessed from the most recent tissue biopsy taken at the time of presentation with recurrent or metastatic disease.
  17. To fulfill the requirement for ER+ disease by local testing, a tumor must express the ER immunohistochemistry, as defined in the relevant American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.
  18. HER2 status should be determined by local testing, as defined in the relevant ASCO/CAP Guidelines.
  19. Must have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 1.
  20. Must be able to comply with outpatient treatment, laboratory monitoring, imaging, and required clinic visits for the duration of trial participation.

排除标准:Exclusion Criteria:

  1. Phase 1a (Cohort A1 and A2) only: Previously received radiopharmaceutical or radioligand therapy. For participants with prostate cancer, prior ¹⁷⁷Lu-prostate-specific membrane antigen (PSMA) is permitted.
  2. Has a history of ongoing acute pancreatitis within 1 year of screening.
  3. Previously received any prior hemi-body or whole-body radiotherapy, or prior external beam radiation therapy (EBRT) to greater than 25% of the bone marrow.
  4. A bone superscan, defined as a bone scan that demonstrates markedly increased skeletal radioisotope uptake relative to soft tissues in association with absent or faint genitourinary tract activity.
  5. Has evidence of ongoing and untreated urinary tract obstruction or unmanageable urinary incontinence.
  6. Have known active hepatitis B virus (HBV). Exception: Individuals with chronic HBV if they:
  7. Have positive HBsAg
  8. Are on suppressive antiviral therapy, as allowed per local regulations prior to C1D1
  9. Remain on the same antiviral treatment throughout study, and should follow local standards for continuation of therapy after completion of trial therapy.
  10. Have undetectable HBV DNA ≤14 days of C1D1.
  11. Have known active hepatitis C virus (HCV). Exception: Individuals previously treated for HCV if they:
  12. Completed curative antiviral therapy.
  13. Have an HCV viral load below the limit of quantification ≤14 days of C1D1 and.
  14. Are positive for anti-HCV antibodies and negative for HCV ribonucleic acid (RNA) before randomization.
  15. Have untreated human immunodeficiency virus (HIV) infection. Exception: Individuals who have well-controlled HIV infection/disease and they:
  16. Are on a stable and permitted antiretroviral therapy (ART) regimen without changes in drug or dose, for at least 4 weeks prior to C1D1
  17. Have a viral load of <400 copies/mL ≤14 days of C1D1.
  18. Have a CD4+ T-cell count ≥350 cells/mL ≤14 days of C1D1.
  19. Have not had an opportunistic infection within the past 12 months.
  20. Has an active second malignancy unless in remission with life expectancy greater than 2 years.
  21. Has known hypersensitivity to any component or excipient of LY4257496.

引自 ClinicalTrials.gov, NCT07114601, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07114601,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07114601